1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Xiamen Amoytop Biotech Co., Ltd. Class A

Xiamen Amoytop Biotech Co., Ltd. Class A

SSSE:688278
45.17
CNY
-1.60
(-3.42%)
22.21BMarket Cap
Oct 23Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.86
0.63
1.12
2.04
1.98
2.81
3.78
5.18
6.91
9.07
- -
Basic EPS, GAAP
0.09
0.01
0.04
0.18
0.29
0.45
0.71
1.37
2.03
2.53
- -
Free Cash Flow per Basic Share
-0.14
-0.07
0.19
0.22
-0.07
0.11
0.36
0.55
0.44
1.16
- -
Dividend per Share
0.01
0.01
0.01
0.01
0.03
0.05
0.1
0.21
0.41
0.62
0.62
Book Value per Share
1.33
1.34
1.39
1.56
2.46
2.85
3.46
4.61
6.28
8.45
7.6
Tangible Book Value per Share
0.65
0.64
0.74
0.96
1.85
2.09
2.62
3.75
5.34
7.37
6.55
Basic Weighted Avg Shares
326
517
400
357
402
403
404
405
408
408
408
Sales/Revenue/Turnover
280
323
448
730
794
1,132
1,527
2,100
2,817
3,696
- -
Operating Margin (%)
13.8
5.7
9.12
17.36
19.31
21.05
26.02
32.52
34.33
33.53
- -
Depreciation Expense
17
26
38
38
38
43
48
59
75
125
- -
Net Income, GAAP
29
5
16
64
117
181
287
555
828
1,031
- -
Effective Tax Rate (%)
10.8
32.61
- -
29.36
16.18
15.83
19.36
13.3
11.11
12.26
- -
Profit Margin (%)
10.46
1.6
3.57
8.81
14.68
16
18.8
26.45
29.38
27.9
- -
Working Capital
170
177
244
295
655
657
688
937
1,406
2,023
2,190
LT Debt
- -
- -
- -
- -
9
9
6
4
3
128
712
Total Equity
478
483
499
564
1,000
1,161
1,408
1,876
2,553
3,450
3,104
Return on Invested Capital (%)
- -
1.18
- -
13.5
15.82
18.62
24.55
34.64
37.79
34.5
- -
Return on Capital (%)
- -
1.4
- -
11.52
14.34
16.42
22.08
33.67
37.24
33.37
- -
Return on Common Equity (%)
- -
1.08
3.26
12.1
14.91
16.76
22.35
33.83
37.37
34.36
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
47
29
58
LT Borrowings
104
135
684
LT Finance Leases
24
23
28
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
408
408
408
Market Capitalization
34,157
26,451
22,206

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,730
2,785
2,777
Cash, Cash Equivalents & STI
1,016
1,087
948
Accounts Receivable, Net
1,069
945
1,128
Inventories
415
431
446
Total Current Liabilities
707
581
587
Payables & Accruals
- -
- -
- -
ST Debt
47
29
58
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
28.35%
35.1%
Free Cash Flow
- -
32.08%
163.96%
Net Income, GAAP
- -
56.19%
24.61%
Sales/Revenue/Turnover
- -
36.07%
31.18%
Total Cash Common Dividend
- -
83.27%
51.61%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
545
645
765
862
2,817
2025
673
837
- -
1,216
3,696
2026
798
1,039
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.32
0.43
0.61
0.67
2.03
2025
0.45
0.6
- -
0.89
2.53
2026
0.4
0.77
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.41
2025
- -
0.62
- -
- -
0.62
2026
- -
0.62
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Li Sun
Full Time Employees
3,644
Sector
Health technology
Industry
Biotechnology
Address
No. 330 Wengjiao Road Xiamen FU China 361028
IPO Date
Jan 17, 2020
Website
amoytop.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Xiamen Amoytop Biotech Co., Ltd. (688278.SS) engages in the research, development, production, and sale of recombinant protein drugs, primarily focusing on treatments for viral hepatitis, malignant tumors, and immunotherapy applications. The company offers a portfolio of branded drug products including Pegbing (Mipeginterferon alfa-2b Injection), Pegpesen (Inpegsomatropin Injection, the world's first Y-shaped 40-kDa PEGylated long-acting growth hormone), Pegneugen (Pegfilgrastim Injection), TOPLEUCON (rHuGM-CSF, Molgramostim), TOPNEUTER (rHuG-CSF, Filgrastim), and TOPMEGA (rHuIL-11, Oprelvekin); active pharmaceutical ingredients (APIs); and bio-reagents such as interleukins (e.g., IL-4, IL-15), interferons (e.g., IFN-gamma), growth factors, tumor necrosis factor-alpha (TNF-alfa), stem cell factor (SCF), and enzymes. Founded in 1996 and headquartered in Xiamen, China, the company operates primarily in China with exports to international markets and employs over 2,400 people across its cGMP-compliant facilities. In recent developments, Amoytop Biotech listed on the Shanghai Stock Exchange STAR Market in 2020 as the first biomedical stock from Fujian Province; launched Pegneugen (Pegfilgrastim), a national Class 1 new drug, in 2023; received National Medical Products Administration approval for Pegpesen (Inpegsomatropin Injection) in May 2025; entered a clinical trial collaboration agreement with Aligos Therapeutics, Inc. in July 2024; and completed the acquisition of gene therapy company Skyline Therapeutics in 2025. The firm targets biopharmaceutical segments including liver disease, oncology, metabolic diseases, and systemic immunity solutions through cytokine drugs, supported by core platforms in Y-shaped PEG modification technology and postdoctoral research capabilities.